Baltruškevičienė, E. et al. 2016. Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. Acta medica Lituanica. 23, 1 (Apr. 2016), 24–34. DOI:https://doi.org/10.6001/actamedica.v23i1.3267.